Trials / Completed
CompletedNCT02297984
Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke
Changes of Serum Neuroglobin and HIF-1α Concentrations in Early-phase of Acute Ischemic Stroke
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Shanghai 6th People's Hospital · Academic / Other
- Sex
- All
- Age
- 42 Years – 76 Years
- Healthy volunteers
- Not accepted
Summary
Neuroglobin has shown rich neuroprotective effects against cerebral ischemia and hypoxia, and therefore has the potential to impact outcomes after acute ischemic stroke. Hypoxia inducible factor (HIF)-1α is neuroprotective in several models of experimental brain injury and is increased in brain after acute cerebral infarction in humans and experimental animals.The investigators sought to examine the changes in serum neuroglobin and HIF-1α concentrations in patients with acute ischemic stroke during the initial 96-h period after stroke and assessed the relation between them and the relation of them to prognosis of such patients with acute ischemic stroke.
Conditions
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-09-01
- Completion
- 2014-10-01
- First posted
- 2014-11-21
- Last updated
- 2020-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02297984. Inclusion in this directory is not an endorsement.